Eleven Biotherapeutics

Press Releases
 
Press Releases
Date Title and Summary View
March 20, 2017 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing a broad pipeline of novel product candidates based on its Targeting Protein Therapeutics (TPTs) platform, today announced that Stephen Hurly, President and Chief Executive Officer, ...
March 1, 2017 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing a broad pipeline of novel product candidates based on its Targeting Protein Therapeutics (TPTs) platform, today announced that Stephen HurlPy, President and Chief Executive Officer, ...
February 7, 2017 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing a broad pipeline of novel product candidates based on its Targeting Protein Therapeutics (TPTs) platform, today announced that Stephen Hurly, President and Chief Executive Officer, ...
November 14, 2016 -Management to host conference call today at 8:30 a.m. ET- CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing a broad pipeline of novel product candidates based on its Targeting Protein Therapeutics (TPTs) platform...
November 4, 2016 -Conference call scheduled for November 14, 2016 at 8:30 a.m. ET- CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a late stage clinical oncology company advancing a broad pipeline of novel product candidates based on a Targeting Protein Therapeutics (TPTs) pl...
September 21, 2016 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. (Nasdaq: EBIO), today reported that in connection with the appointment of each of Stephen Hurly as President and Chief Executive Officer, Arthur P. DeCillis, M.D., as Chief Medical Officer, Glen MacDonald, Ph.D., as Chief Scientific Officer...
September 21, 2016 -Viventia's Lead Product Candidate, ViciniumTM, being developed for high-grade non-muscle invasive bladder cancer, with topline Phase 3 data expected in 1H 2018- -ProxiniumTM being developed for late-stage squamous cell carcinoma of the head and neck with Phase 2 initiation planned for ea...
August 16, 2016 Eleven entitled to $30 million payment CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced the effectiveness of the exclusive licensing deal ...
August 12, 2016 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today reported financial results for the second quarter ended June 30, 2016 and provided a review of recent business highlights...
July 7, 2016 Eleven entitled to receive $22.5 million milestone payment for IND effectiveness CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced...
FirstPrevious
2
... NextLast
Add to Briefcase = add release to Briefcase
NASDAQ: EBIO
Price:
1.51
Change:
- 0.03
Day High:
1.55
Day Low:
1.50
Volume:
90,696
3:59 PM ET on July 21, 2017
Delayed at least 20 minutes.